Abstract
We report long-term virologic response to etravirine and tenofovir/emtricitabine in four HIV-1-infected patients who had prior standard genotypic resistance testing showing an isolated K103N mutation (three acquired, one transmitted). In three patients tested, the K103N mutation was detected in cellular HIV-1 DNA whereas remaining suppressed on etravirine plus tenofovir/emtricitabine.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / therapeutic use*
-
Asparagine
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Drug Resistance, Multiple, Viral / drug effects
-
Drug Resistance, Multiple, Viral / genetics
-
Drug Therapy, Combination
-
Emtricitabine
-
Female
-
Genotype
-
HIV Seropositivity / drug therapy*
-
HIV Seropositivity / genetics
-
HIV-1 / drug effects
-
HIV-1 / genetics*
-
Humans
-
Lysine
-
Male
-
Mutation*
-
Nitriles
-
Organophosphonates / administration & dosage
-
Organophosphonates / therapeutic use*
-
Pyridazines / administration & dosage
-
Pyridazines / therapeutic use*
-
Pyrimidines
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Tenofovir
Substances
-
Anti-HIV Agents
-
Nitriles
-
Organophosphonates
-
Pyridazines
-
Pyrimidines
-
Reverse Transcriptase Inhibitors
-
etravirine
-
Deoxycytidine
-
Asparagine
-
Tenofovir
-
Emtricitabine
-
Adenine
-
Lysine